U.S. markets close in 4 hours 33 minutes

Guardant Health, Inc. (GH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
122.78+2.79 (+2.33%)
As of 11:26AM EDT. Market open.

Guardant Health, Inc.

505 Penobscot Drive
Redwood City, CA 94063
United States
855 698 8887
http://guardanthealth.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees864

Key Executives

NameTitlePayExercisedYear Born
Dr. AmirAli TalasazPres, COO & Chairman289.72k24.46M1980
Dr. Helmy Eltoukhy Ph.D.Co-Founder, CEO & Director275.66k15.14M1979
Mr. John G. SaiaSr. VP, Gen. Counsel & Corp. Sec.651.29kN/A1973
Mr. Michael J. WileyHead of Corp. Affairs640.38k1.65M1976
Mr. Michael BellChief Financial OfficerN/AN/A1969
Mr. Kumud KaliaChief Information OfficerN/AN/AN/A
Ms. Amelia MerrillVP of PeopleN/AN/AN/A
Dr. Richard B. LanmanAdvisorN/AN/A1955
Mr. Mark JacobsteinChief User Engagement OfficerN/AN/AN/A
Mr. Andy AmentSr. VP of OperationsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

Corporate Governance

Guardant Health, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.